AstraZeneca defends Crestor
This article was originally published in The Tan Sheet
Executive Summary
A Circulation article linking Crestor (rosuvastatin) to a higher risk of muscle and kidney toxicity compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca says May 23. The study by Alawai Alsheikh-Ali, Tufts-New England Medical Center, et al., "attempts to draw conclusions that simply cannot be drawn from adverse event reporting data," the firm says. The findings were released in May (1"The Tan Sheet" May 30, 2005, p. 6)...
You may also be interested in...
Circulation Articles Question Crestor, Stress Statin Selection Complexity
Appropriate selection of cholesterol-lowering statins is complicated by determining desirable LDL levels for a patient and comparing side-effect profiles of drugs in the class, an editorial in the May 23 issue of Circulation maintains
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.